Clinical risk management of Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum.
Clinical risk management concedes that risk is inherent to all health-care processes. Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but potentially life-threatening reactions to medications. Risk management should be considered prior to starting, during, and after therapy. Prior to starting therapy, risks that need to be assessed include any specific patient groups that may be at greater risk for the development of SJS/TEN. Gene testing is in place for Chinese and Thai patients who are going to be exposed to carbamazepine. During therapy, it is important to recognize SJS/TEN as a possible adverse drug reaction. Diagnostic criteria have changed, and more data exist on drugs with an increased risk. Although there is no standardized treatment for all patients with SJS/TEN, options that have been used include cyclosporine, corticosteroids, and intravenous immunoglobulin. Standards of care are usually defined locally, but new treatments, such as amniotic membrane support for ocular damage, may need to be considered. Good communication skills are needed to allow practitioners to show empathy and to provide disclosure. Risk management after a reaction includes skills in acknowledging bad outcomes or error; freedom to say "sorry" as defined by "apology laws," and knowing the rights provided by "Quality Assurance Conferences," where the information discussed is protected. In other words, the patient is best supported after an event like SJS/TEN if the practitioner is knowledgeable about optimal care standards and their legal rights and obligations.
Division of Clinical Pharmacology and Toxicology, Synnybrook Health Sciences Centre, Toronto, Ontario, Canada.
Sandra
S
Knowles
Neil H
NH
Shear
D003142:Communication; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D011787:Quality of Health Care; D018570:Risk Assessment / Q000379:methods; D012307:Risk Factors; D012308:Risk Management / Q000379:methods; D013262:Stevens-Johnson Syndrome / Q000139:chemically induced / Q000209:etiology / Q000517:prevention & control*